Tenderwize
Zurück zur Suche

Open-house rebate contracts for risperidone parenteral depot products

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Mar 31, 2027 · 218 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Risperidon, als parenterale Depotform, ATC N05AX08

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

Submission must be in original paper form and electronic submission is not allowed, creating courier and timing risk.

If the product is not already listed in Lauer-Taxe, the bidder must provide AMIce evidence and possibly supplementary p...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Non-exclusive open-house rebate contracts for pharmaceutical products containing risperidone in parenteral depot form.
  • Uniform contract conditions for all participating pharmaceutical companies; no individual negotiations.
Vollständige Zusammenfassung anzeigen

Open-house supply arrangement for non-exclusive pharmaceutical rebate contracts for risperidone in parenteral depot form (ATC N05AX08) offered by AOK Rheinland-Pfalz/Saarland. The notice states that this is not a public contract award in the usual procurement sense, but a transparency publication for contract access. One lot is present. Contracting is open to interested pharmaceutical companies on uniform terms, with no individual negotiations. The earliest contract start is 2025-06-01 and the maximum term is 24 months. Submission is by original paper documents; electronic submission is not allowed. Procurement documents are available via the notice link, but no extracted contract documents were provided for analysis.

Risiken

Submission must be in original paper form and electronic submission is not allowed, creating courier and timing risk.

If the product is not already listed in Lauer-Taxe, the bidder must provide AMIce evidence and possibly supplementary p...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Only approved and marketable medicines in Germany may be supplied under the contract.
  • If the product is already listed in Lauer-Taxe as marketable, this is deemed proven.

Administrative

  • If not yet listed in Lauer-Taxe at submission time, the contractor must provide an extract from the public AMIce database and, where needed, supplementary evidence such as...

Auftraggeber

Lose (1)

LOT-0001

Open-house rebate contracts for risperidone parenteral depot products

Non-exclusive open-house rebate contracts for medicinal products containing risperidone in parenteral depot form (ATC N05AX08). The scope is limited to the named active substance/form. The notice excludes medicines listed as children's medicines under the BfArM list pursuant to Section 35(5a) SGB V. Contract terms are uniform for all participants and no individual negotiation is foreseen. Contracts may start on the first day of a month within the 24-month period, with the earliest start on 2025-06-01 and final end no later than 24 months after that date. The lot is based on structured notice data and XML notice text.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

May 2025 - May 2027

Kategorie

Pharmaceutical products

Frist

Deadline Mar 31, 2027

Vergabedetails

Veröffentlichungsdatum
10 Apr 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
237162-2025

Dokumente (1)

Ähnliche Ausschreibungen